Key Drivers
- Strong cashflow
- High leverage
- Large intangibles
AIAI Summary
Collegium's evolution from a single pain‑product story into a hybrid specialty platform with accelerating Jornay PM growth and an acquisitive push (AZSTARYS) materially reframes the thesis toward near‑term revenue accretion—but the critical action for investors is to monitor Jornay gross‑to‑net trends and timely AZSTARYS integration/deleveraging, since small G‑to‑N slips or execution missteps could quickly stress the elevated debt-funded balance sheet.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cashflow
- •High leverage
- •Large intangibles
Colliers generates strong margins and unusually high free cash flow relative to its market cap but carries significant solvency and asset-quality risk from heavy long-term debt and large intangibles.
Price Behavior
Key Price Behavior Insights:
- •Sharp downtrend
- •RSI oversold
- •Support cluster
Stock is in a clear downtrend, down roughly 20% over the last month to 2026-03-20 and now oversold (RSI ~24), which raises the chance of a short-term bounce but downside risk persists until support is confirmed.
Rapid ~20% drop over the last month increases downside risk and suggests sentiment/fundamental reassessment
Sentiment & News
Key News Insights:
- •Record revenue
- •AZSTARYS deal
- •ADHD expansion
Collegium reported record 2025 revenues and Q4 sales growth while missing EPS, and is pivoting into a broader ADHD franchise via the accretive $650M AZSTARYS deal and JORNAY PM to drive 2026 growth.
The AZSTARYS acquisition and JORNAY PM should accelerate near‑term revenue and EBITDA accretion, supporting a strategic shift toward ADHD while the EPS miss is a short‑term market signal
Similar Companies in Healthcare
Other companies in the same sector with AI ratings